October 23, 2008Reckoner
A Business Snapshot
Q2 FY 09
Overall revenues at Rs. 16.2 billion ($348 mn) in Q2 FY09 as against Rs. 12.5 billion ($268
mn) in Q2 FY08; represent a growth of 30%. YOY
EBITDA at Rs. 2.7 billion($59 mn) in Q2 FY09 as against Rs. 2.2 billion($47 mn) in Q2 FY08.
Key growth drivers: North America, Germany and Russia.
Operating income grew by 78% to Rs. 2 billion ($43 million) in Q2 FY09 as against Rs. 1.1 billion ($24 million) in Q2 FY08.
During the quarter, the company launched 35 new generic products, filed 25 new generic product registrations and filed 21
Revenues from Global Generics business at Rs. 11.2 billion ($240 million) in Q2 FY09 as against Rs. 8.0 billion ($172
million) in Q2 FY08. YoY growth of 40% driven by key markets of North America, Russia and Germany.
Revenues from North America at Rs. 3.2 billion ($69 mn) in Q2 FY09 as against Rs. 2.1 billion ($45 mn) in Q2 FY08.
YoY growth of 54% in North America driven by a combination of volume growth in key existing products,
new product launches in the last 12 months and acquisition of Shreveport facility.
Revenue from Shreveport facility at Rs. 428 million ($9 million) in Q2 FY09.
3 new products launched in Q2 FY09.
During the quarter, the Company filed 2 ANDAs taking the total filings to 128. Total of 66 ANDAs pending at the
USFDA addressing innovator sales of $48 billion as per IMS December 2007.
Revenues from Europe at Rs 3.2 billion ($69 million) in Q2 FY09 as against Rs. 2.2 billion ($47 million) in Q2 FY08
Revenues from betapharm increase by 68% to Rs. 2.8 billion ($60 million) in Q2 FY09 from Rs. 1.7 billion ($36
million) in Q2 FY08. This growth was driven by the contribution from the launch of a seasonal vaccine (in-licensed)
as well as volume growth in existing products.
Revenues from Rest of Europe at Rs. 392 million ($8 million) in Q2 FY09 as